Species of sphingolipids have been associated with prediabetes risk. Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA) discusses the outcome of a longitudinal study conducted at the University of Tennessee which followed a diverse cohort of patients who initially presented with ‘normal’ glucose metabolism but bifurcated into two subgroups: those with ‘normal’ glucose levels (‘non-progressors’) and those who have progressed to prediabetes (‘progressors’).
The abstract ‘Association of Ceramide and Sphingolipid Species with Incident Prediabetes among Offspring of Parents with Type 2 Diabetes’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Your study determined the association between sphingolipids and prediabetes risk – please can you outline the study design and key findings? (0:41)
- Why was it important to include a diverse cohort of patients? (10:14)
Disclosures: Samuel Dagogo-Jack has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Watch out for Danatech! The latest online resource for diabetes healthcare professionals
touchENDOCRINOLOGY spoke to Leslie Kolb (Chief Science Practice and Learning Officer) and Dana Moreau (Senior Product Manager of Danatech) from the Association of Diabetes Care and Education Specialists (ADCES) to discuss the exciting launch of Danatech. This innovative online resource allows healthcare professionals to research and review the latest devices and mobile apps and offers […]
Riccardo Candido, ADA 2022: Intensification strategies following GLP1-RA therapy failure in type 2 diabetes, the RESTORE-G real-world study
The RESTORE-G real-world study investigated the intensification strategies following GLP1-RA therapy failure in type 2 diabetes. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the design of the study, the key findings and the implications for clinical practice. The abstract entitled ‘Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 […]
Riccardo Candido, ADA 2022: GLP1-RA therapy for type 2 diabetes and the intensification strategies following treatment failure
Intensification strategies are available if patients with type 2 diabetes experience GLP1-RA therapy failure. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the current place of GLP1-RA therapy for the treatment of type 2 diabetes and the intensification strategies available following failure. Dr Riccardo Candido presented an abstract entitled ‘Treatment Intensification after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!